Clinical trials: Psychosis; Acute
Schizophrenia
Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients
The purpose of the study is to compare the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme with to the current approved label titration.
- Trial name
- NCT00254787
- Testing
- IR (Immediate-Release) quetiapine fumarate (drug)
- Where
- 6 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Schizophrenia
Acute Psychological Effects of High Intensity Exercise With Schizophrenia
The purpose of this study is to study the acute psychological effects in patients with schizophrenia after one session of high intensity exercise.
- Trial name
- NCT01310998
- Testing
- High intensity exercise
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Schizophrenia, Psychosis
Study of Immunotherapy in Autoantibody Positive Psychosis
Psychosis is a mental health problem that causes people to perceive or interpret things differently from those around them, often involving hallucinations or delusions.
- Conditions
- Schizophrenia, Psychosis, Auto Immune Disorders
- Trial name
- SINAPPS-1 (NCT02449746)
- Testing
- Plasma Exchange, Intravenous immunoglobulin
- Where
- 5 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Cambridge
Schizophrenia
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.
- Trial name
- NCT01104766
- Testing
- Cariprazine, Aripiprazole
- Where
- 58 sites in United States, Romania and 2 more
- Volunteers
- 617 people
- Sponsor
- Forest Laboratories
Mental Disorder
Evaluation of Home Treatment for Acute Psychiatric Care
The study's goal is to evaluate whether home treatment is an effective and efficient alternative to inpatient care for people with acute mental illness.
- Trial name
- NCT03320720
- Testing
- Home Treatment, Treatment-as-usual
- Where
- Switzerland
- Volunteers
- 700 people
- Sponsor
- Psychiatric University Hospital, Zurich
Schizophrenia
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
- Trial name
- NCT02634346
- Testing
- ALK3831, Olanzapine
- Where
- 31 sites in United States, Bulgaria and 2 more
- Volunteers
- 403 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
The purpose of this study is to examine whether olanzapine, compared to risperidone, can provide more adequate and timely control of behavioral agitation in acutely ill subjects with schizophrenia.
- Trial name
- NCT00485498
- Testing
- Olanzapine Hydrochloride, Risperidone
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
The purpose of this trial is to assess the effect of asenapine 2.5 and 5 mg sublingually twice daily (BID) compared with placebo in the treatment of schizophrenia (overall symptoms) as measured by the Positive and Negative…
- Trial name
- NCT01617187
- Testing
- Asenapine, Olanzapine
- Volunteers
- 360 people
- Sponsor
- Organon and Co
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR)
This is an 8-week, multi-centre, Open-label, non-comparative study to evaluate the efficacy and safety of Quetiapine XR with daily dose 400mg-800mg used as mono-therapy in the treatment of acute schizophrenic patients.
- Trial name
- QUENCH (NCT00779506)
- Testing
- Quetiapine Fumarate XR
- Where
- 7 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- AstraZeneca
Schizophrenia
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)
The purpose of this study was to evaluate the efficacy and safety of elpipodect at a range of doses (8 mg, 16 mg, and 24 mg once daily [QD]) in adult participants who have an acute episode of schizophrenia according to Diagnostic…
- Trial name
- NCT04624243
- Testing
- Elpipodect, Risperidone
- Where
- 121 sites in United States, Bulgaria and 10 more
- Volunteers
- 499 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
- Trial name
- NCT03345979
- Testing
- Aripiprazole Lauroxil, Paliperidone Palmitate
- Where
- 16 sites in United States
- Volunteers
- 200 people
- Sponsor
- Alkermes, Inc.
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Schizoaffective Disorder
α-N-acetylgalactosaminidase in Schizoaffective Disorder
Schizoaffective disorder (SAD) is a severe psychiatric condition characterized by the coexistence of psychotic symptoms and mood episodes.
- Trial name
- NCT07673718
- Where
- Turkey (Türkiye)
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Elazığ Mental Health and Diseases Hospital
Schizophrenia
Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia
This is a phase 3, multicenter, randomized, active-controlled trial to assess the efficacy and safety of aripiprazole Intramuscular Depot in the acute treatment of adults with schizophrenia.
- Trial name
- NCT03172871
- Testing
- Aripiprazole IM Depot, Aripiprazole tablet
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia
The purpose of this study is to explore changes in efficacy, cognitive functioning, and safety of flexibly-dosed Brexpiprazole monotherapy in subjects with acute schizophrenia
- Trial name
- NCT02054702
- Testing
- Brexpiprazole, Aripiprazole
- Volunteers
- 97 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).
- Trial name
- PREVAIL (NCT01527305)
- Testing
- Paliperidone palmitate
- Where
- 21 sites in China, Malaysia and 2 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Cardio Risk of Acute Schizophrenia Olanzapine Duke
Primary Objective: To compare added metformin and/or added simvastatin versus no intervention in reducing or eliminating increased cardiovascular risk (as estimated by elevation in non-HDL cholesterol levels) during the treatment…
- Trial name
- CRASOD (NCT00672464)
- Testing
- Olanzapine, Metformin, Simvastatin
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Acute Episode
An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)
This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control.
- Trial name
- NCT03055338
- Testing
- Elpipodect, Risperidone
- Where
- 28 sites in United States
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC